targeting the pi3k pathway in patients who fail jak inhibitor therapy
Published 1 year ago • 76 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:18
the current status of pi3k inhibitors in hematological malignancies and challenges to overcome
-
3:19
therapeutic options following failure to jak inhibitors
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
2:56
side effects of novel pi3k inhibitors
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
46:06
[quality] q3a(r2)
-
30:53
data explosion in medical imaging
-
17:04
the medical minute - ep. #10 - guardant 360 - a new tool in the cancer fighting toolkit
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
7:10
bomedemstat in jak inhibitor-resistant myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
2:37
the role of jak inhibitors in reducing gvhd severity
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
7:24
targeting the pi3k-akt-mtor pathway
-
1:24
understanding aberrant signaling pathways to prevent resistance to jak2 inhibitors in mpns
-
3:23
myelofibrosis: updates on jak inhibitors
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
42:18
targeting the pi3k pathway in the therapy of breast cancer
-
1:51
the use of btk inhibitors in r/r and treatment-naïve patients with wm
-
4:25
a potential new treatment for pnh: c3 inhibitor pegcetacoplan reduces markers of hemolysis